Immune privilege

Toastique Launches New Be Well Juice Cleanses Direct to Consumers

Retrieved on: 
Monday, August 28, 2023

WASHINGTON, Aug. 28, 2023 /PRNewswire-PRWeb/ -- Toastique, a leading health and wellness brand, is excited to announce the launch of its new product line, Be Well Juice Cleanses. The cleanses are available for direct delivery to consumers, offering a convenient and accessible way to enjoy the benefits of juice cleansing.

Key Points: 
  • WASHINGTON, Aug. 28, 2023 /PRNewswire-PRWeb/ -- Toastique, a leading health and wellness brand, is excited to announce the launch of its new product line, Be Well Juice Cleanses.
  • The cleanses are available for direct delivery to consumers, offering a convenient and accessible way to enjoy the benefits of juice cleansing.
  • Overall, the new Be Well Juice Cleanses are designed to be flexible and adaptable to individual preferences and health goals.
  • "Especially with juice cleanses, it is really about your lifestyle," said Nicole Valentin, Director of Strategy & Development at Toastique.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, May 15, 2023

“This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.

Key Points: 
  • “This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
  • “Furthermore, data from an ex vivo human AA disease model demonstrates the potential for farudodstat to protect against immune privilege collapse in AA.
  • This study investigated whether farudodstat, a DHODH inhibitor, has potential in the treatment of AA using an innovative ex vivo model for AA.
  • Together, the findings highlight the potential for farudodstat as a novel therapy for AA.

ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, April 24, 2023

Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.

Key Points: 
  • Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.
  • “The abstracts published today highlight the potential of eblasakimab to offer important differentiated benefits for AD patients.
  • Spontaneous neuronal activity was not impacted by IL-13 treatment but was increased with IL-4 treatment, which was also effectively reduced by eblasakimab.
  • This indicates that direct impact on neuronal responses may contribute to reduction of chronic itch demonstrated in AD patients treated with eblasakimab.

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

Retrieved on: 
Wednesday, March 8, 2023

Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.

Key Points: 
  • Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
  • ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website .
  • He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

Retrieved on: 
Tuesday, February 28, 2023

AA is associated with severe psychological burden and has limited treatment options, affecting over 700,000 patients in the US.

Key Points: 
  • AA is associated with severe psychological burden and has limited treatment options, affecting over 700,000 patients in the US.
  • The inhibition of DHODH is an established mechanism for the treatment of several autoimmune diseases.
  • Farudodstat, a highly selective DHODH inhibitor, is 30-fold more potent than approved drugs in its class and has a well-tolerated safety profile.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical’s website .

ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals

Retrieved on: 
Tuesday, August 31, 2021

Further, data revealed that intratumoral injection of ImmunoGenesis' STING agonist into orthotopic pancreatic lesions unmasks sensitivity to checkpoint blockade, further indicating the potential of its STING agonist to help overcome immunotherapy resistance in cold tumors.

Key Points: 
  • Further, data revealed that intratumoral injection of ImmunoGenesis' STING agonist into orthotopic pancreatic lesions unmasks sensitivity to checkpoint blockade, further indicating the potential of its STING agonist to help overcome immunotherapy resistance in cold tumors.
  • "These two published studies show strong preclinical proof of concept of our STING agonist against cold cancersincluding pancreatic and brain cancersrefractory to currently available immunotherapy," said James Barlow , ImmunoGenesis President and CEO.
  • "This further reveals the potential for ImmunoGenesis' STING agonist to be a foundational treatment in immunologically resistant cancers such as GBM."
  • The investigators tested the STING agonist by injection directly into the glioblastoma of five dogs that had previously been diagnosed with the cancer.

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases

Retrieved on: 
Wednesday, June 23, 2021

At Abata, were harnessing Tregs as targeted therapies to alter the course of serious autoimmune disease and succeed where others have failed.

Key Points: 
  • At Abata, were harnessing Tregs as targeted therapies to alter the course of serious autoimmune disease and succeed where others have failed.
  • Abatas autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered.
  • This enables Abatas Tregs to target the site of disease for a robust effect without imposing systemic immune suppression.
  • Abatas Treg cell therapy will treat patients with the genetic HLA haplotype DR3, an estimated 75% of patients.

How Dying Cells Prevent Dangerous Immune Reactions - New Receptor for Treatment of Autoimmune Disease Validated by German Cancer Research Centre Using Attana Technology

Retrieved on: 
Thursday, January 16, 2020

Dying cells in the body can keep the immune system in check, thus preventing unwanted immune responses against the body's own tissues.

Key Points: 
  • Dying cells in the body can keep the immune system in check, thus preventing unwanted immune responses against the body's own tissues.
  • Prof. Krammer's group at the German Cancer Research Center have now identified the receptor Dectin-1 on immune cells that activates this protective mechanism and can, thus, prevent dangerous autoimmune reactions in which the immune system attacks the body's own tissues.
  • Dying cells in the body can keep the immune system in check, thus preventing unwanted immune responses against the body's own tissues.
  • Scientists from the German Cancer Research Center have now identified a receptor on murine immune cells that activates this protective mechanism and can thus prevent dangerous autoimmune reactions in which the immune system attacks the patient's own body tissues.